Vanguard Group Inc. Grows Stake in Phreesia, Inc. $PHR

Vanguard Group Inc. grew its stake in Phreesia, Inc. (NYSE:PHR) by 2.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,936,515 shares of the company’s stock after acquiring an additional 113,405 shares during the quarter. Vanguard Group Inc. owned about 8.40% of Phreesia worth $126,177,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in PHR. LPL Financial LLC purchased a new position in shares of Phreesia in the 4th quarter valued at $216,000. Wells Fargo & Company MN increased its holdings in shares of Phreesia by 48.7% in the 4th quarter. Wells Fargo & Company MN now owns 28,915 shares of the company’s stock valued at $728,000 after acquiring an additional 9,476 shares during the period. Invesco Ltd. increased its holdings in shares of Phreesia by 0.9% in the 4th quarter. Invesco Ltd. now owns 40,249 shares of the company’s stock valued at $1,013,000 after acquiring an additional 357 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Phreesia in the 4th quarter valued at $379,000. Finally, Barclays PLC increased its holdings in shares of Phreesia by 120.4% in the 4th quarter. Barclays PLC now owns 209,209 shares of the company’s stock valued at $5,264,000 after acquiring an additional 114,280 shares during the period. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Phreesia

In other Phreesia news, Director Mark Douglas Smith sold 7,000 shares of Phreesia stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $29.00, for a total transaction of $203,000.00. Following the completion of the sale, the director owned 37,353 shares of the company’s stock, valued at approximately $1,083,237. The trade was a 15.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Allison C. Hoffman sold 1,245 shares of Phreesia stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $26.89, for a total value of $33,478.05. Following the sale, the general counsel directly owned 136,978 shares of the company’s stock, valued at approximately $3,683,338.42. This represents a 0.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 53,882 shares of company stock worth $1,513,007 in the last quarter. 5.50% of the stock is owned by insiders.

Phreesia Stock Up 3.6%

Shares of PHR stock opened at $28.70 on Friday. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $30.53. The stock’s fifty day moving average price is $27.41 and its 200 day moving average price is $26.42. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.95 and a quick ratio of 1.95. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -38.78 and a beta of 0.71.

Phreesia (NYSE:PHR) last announced its earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.06. Phreesia had a negative return on equity of 16.23% and a negative net margin of 9.83%.The firm had revenue of $115.94 million for the quarter, compared to the consensus estimate of $115.00 million. During the same period in the previous year, the business earned ($0.05) EPS. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. On average, research analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. KeyCorp lifted their price target on Phreesia from $28.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, July 14th. Wall Street Zen upgraded Phreesia from a “hold” rating to a “buy” rating in a report on Sunday, June 1st. Citigroup reiterated a “buy” rating on shares of Phreesia in a report on Wednesday, May 28th. Truist Financial lifted their price target on Phreesia from $34.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, May 29th. Finally, Canaccord Genuity Group dropped their target price on Phreesia from $35.00 to $34.00 and set a “buy” rating on the stock in a research note on Thursday, May 29th. One analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the stock. According to MarketBeat, Phreesia currently has a consensus rating of “Buy” and a consensus target price of $32.27.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.